Other Financial Information (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Assets held for sale
Cash and cash equivalents		$ 20,566
Marketable securities available for sale		19,863
Trade receivables		14,100
Inventory		8,787
Other current assets		55,862
Property, plant and equipment	58,122	106,583
Identifiable intangible assets		93,456
Investments in unconsolidated entities		17,067
Other noncurrent assets		12,271
Total	58,122	348,555
Liabilities of disposal group
Accounts payable, accrued liabilities and other current liabilities	7,244	36,789
Deferred revenue - current		176
Non-current portion of notes payable		119
Assumed contingent liabilities		9,498
Total	7,244	46,582
Accrued expenses
Compensation	163,824	146,352
Interest	9,635	10,563
Royalties, license fees and milestones	20,924	20,042
Sales returns	8,974	4,779
Rebates, distributor chargebacks and distributor services	201,348	135,916
Clinical trial costs and grants	132,167	100,420
Litigation reserve		80,000
Restructuring reserves	4,514	14,881
Professional services	9,934	10,171
Common share repurchases	33,818	1,243
Canadian pricing settlement	10,000
Other	106,569	67,969
Total	701,707	592,336
Other current liabilities
Contingent consideration -Gloucester acquisition		171,860
Foreign currency forward contracts	23,638	13,122
Sales, use and value added tax	73,978	101,986
Collaboration agreement	17,000
Other	23,808	22,246
Total	138,424	309,214
Other non-current liabilities
Contingent value rights - Abraxis acquisition	60,583	212,042
Contingent consideration -Gloucester acquisition	76,890	81,035
Deferred compensation and long-term incentives	71,262	62,933
Manufacturing facility commitment	17,168	20,577
Foreign currency forward contracts	24,832	33,824
Collaboration agreement	17,000
Other	5,781	5,762
Total	$ 273,516	$ 416,173